E. Ohman J or Asset Management AB Sells 1,938 Shares of Zoetis Inc. $ZTS

Key Points

• E. Ohman J or Asset Management AB reduced its stake in Zoetis Inc. by 9.6%, selling 1,938 shares and holding 18,212 shares valued at approximately $2.84 million by the end of the last reporting period.
• Several institutional investors have recently adjusted their positions in Zoetis, with 92.80% of the company's stock now owned by institutional investors.
• Research analysts currently hold an average rating of "Moderate Buy" on Zoetis, with a consensus target price of $200.88, following mixed ratings changes from various analysts.

E. Ohman J or Asset Management AB decreased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 9.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,212 shares of the company's stock after selling 1,938 shares during the period. E. Ohman J or Asset Management AB's holdings in Zoetis were worth $2,840,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Lindbrook Capital LLC lifted its position in Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after acquiring an additional 65 shares during the last quarter. Quotient Wealth Partners LLC increased its position in shares of Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after purchasing an additional 72 shares in the last quarter. Broadway Wealth Solutions Inc. increased its position in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after purchasing an additional 73 shares in the last quarter. Menard Financial Group LLC lifted its holdings in shares of Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock valued at $305,000 after purchasing an additional 75 shares during the last quarter. Finally, Anchor Investment Management LLC boosted its position in shares of Zoetis by 4.9% in the 1st quarter. Anchor Investment Management LLC now owns 1,618 shares of the company's stock worth $266,000 after purchasing an additional 75 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on ZTS shares. Argus reaffirmed a "buy" rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Stock Performance

NYSE ZTS opened at $146.34 on Tuesday. The stock has a market capitalization of $64.85 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 2.38 and a beta of 0.89. The stock has a 50-day moving average of $152.10 and a 200 day moving average of $157.06. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the business earned $1.56 earnings per share. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.